Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

(2010) Despina Handolias et al.   Pigment Cell & Melanoma Research

Anal Mucosal Melanoma withKIT-Activating Mutation and Response to Imatinib Therapy – Case Report and Review of the Literature

(2009) Imke Satzger et al.   DERMATOLOGY

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

(2008) I Satzger et al.   BRITISH JOURNAL OF CANCER

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

(2008) Jose Lutzky et al.   Pigment Cell & Melanoma Research

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

(2008) Alfonso Quintás-Cardama et al.   Nature clinical practice. Oncology